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Abstract
There is growing concern over the welfare of animals used in research, in particular when these animals develop pathology.
The present study aims to identify the main sources of animal distress and to assess the possible implementation of
refinement measures in experimental infection research, using mouse models of tuberculosis (TB) as a case study. This
choice is based on the historical relevance of mouse studies in understanding the disease and the present and long-
standing impact of TB on a global scale. Literature published between 1997 and 2009 was analysed, focusing on the welfare
impact on the animals used and the implementation of refinement measures to reduce this impact. In this 12-year period,
we observed a rise in reports of ethical approval of experiments. The proportion of studies classified into the most severe
category did however not change significantly over the studied period. Information on important research parameters, such
as method for euthanasia or sex of the animals, were absent in a substantial number of papers. Overall, this study shows
that progress has been made in the application of humane endpoints in TB research, but that a considerable potential for
improvement remains.
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Introduction
In the study of infectious diseases, animal research continues to
be of paramount importance to understand how the immune
system, as well as other systems, responds to pathogens, as well as
for developing and testing new drugs and vaccine candidates. By
experimentally infecting standardized laboratory animals with
pathogenic microorganisms, scientists generate models of infec-
tion, which can be used under controlled conditions and can be
manipulated in a way that would be impossible or ethically
unacceptable in the target human species.
Of note, biomedical research with animals in itself presents an
ethical dilemma between the expected benefit to humans and the
potential harm caused to animals. The Three Rs principle
(Replacement of animal experiments with alternative approaches,
Reduction of animal numbers and Refinement to improve animal
welfare [1]) emerged as a way for scientists to ease this dilemma by
developing research methods that decrease pain and distress.
Nevertheless, the use of animals in research is still controversial,
with recent voices also questioning the translational validity into
humans [2,3]. Thus, how research is to be conducted becomes a
pertinent question from both ethical and scientific perspectives. At
a point in time when research is increasingly challenged by a
critical public, taking such questions seriously is essential if the
scientific community is to be proactive in addressing the need for
animal-based research and retaining public trust in this matter [4].
To assess how animal welfare and refinement have been
considered in animal research on infection, we conducted an
analysis of papers published on biomedical research on TB. This
disease was chosen due to its still enormous global impact [5,6],
with implications in other diseases such as AIDS, since HIV
infected individuals have increased susceptibility to develop TB. In
addition, studies on TB are also expected to increase given the
need a) for a more effective vaccine than Bacillus Calmette-Gue´rin
(BCG); b) for shorter therapeutic strategies; c) for new drugs to
respond to the advent of multi-drug resistant TB; d) to define
surrogates of protection, and; e) for new diagnostic tests [7,8,9,10].
We chose to focus on studies using mice (Mus musculus) as this is the
most widely used species in the field [11] and is expected to remain
important for TB research [12,13].
The first potentially noxious effect of experimental TB infection
in mice arises from the initial innate immune response, a phase
lasting until up to three-four weeks, during which bacilli replicate
exponentially (e.g. [14,15]). In more susceptible mouse strains –
like C3H, 129/Sv, A/J, CBA, DBA/2 or I/St [15,16] – the
immune response fails to control bacillary growth [17] and the
disease progresses towards death, usually as a result of respiratory
insufficiency [14,18]. In more resistant mouse strains, the acquired
immune response typically leads to the stabilization or slow
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evolution of the bacterial load [17,19,20,21]. Animals have been
reported to show no obvious signs of disease during this phase (e.g.
[22,23]). However, the only systematic assessment of symptomol-
ogy following experimental infection with Mycobacterium tuberculosis
reported that a sharp rise in body temperature accompanies
bacillary growth during primary infection, which later on subsides
[24]. Also, a transient (5 days, approximately) sickness behaviour
has been reported to follow infection with BCG, accompanied by
fever and weight loss, in relatively resistant mouse strains [25]. If
left untreated, all M. tuberculosis-infected animals reach a stage of
overtly symptomatic disease, with a strikingly deleterious effect on
their health and wellbeing. This stage is characterized by
increasingly severe clinical signs, manifested externally by respi-
ratory distress, hunched posture, lack of grooming [26], not eating
or drinking, fever and severe cachexia (e.g. [27]) and progressing
to a hypokinetic irresponsive state (‘‘moribund’’) (e.g. [23]). For
situations like these, where animals develop a progressively severe
disease that will ultimately lead to death, implementing humane
endpoints – that is, euthanizing animals to prevent unnecessary
and avoidable suffering – is an important refinement [28,29].
The aim of this study was to identify the causes of animal
distress and assess the implementation of measures to improve the
welfare of research animals used to investigate TB over a 12-year
period.
Results
Trends in the Choice of Murine Models of TB
The number of articles per year increased almost fivefold
between 1997 and 2009, being distributed by year as follows: 17 in
1997; 41 in 1999; 33 in 2001; 50 in 2003; 47 in 2005; 57 in 2007;
and 80 in 2009; with a total of 325 papers for all the years (see
Figure 1 for the triage process). Regarding genetic status of the
animals, the majority of studies (71%, overall for all years) used
non-genetically modified inbred strains. Of these (n = 231), 44%
used solely C57BL/6, 23% BALB/c and 4% other inbred strains;
while the remaining used two (13%) or more than two (6%) inbred
strains. The remaining studies used F1 hybrids (5%) or outbred
mice (6%). Of the studies using genetically modified (GM) mice in
at least one of the experimental groups, 85% used knockout mice,
mostly (82%) on a C57BL/6 background. The use of GM mice did
not change significantly over the time period studied (Figure 2A).
Two articles (out of 325) did not report the strain of mice used.
Information on the sex of animals used was not available in 34%
of articles. Amongst those articles disclosing mouse sex (n = 214),
the great majority (77%) reported using females (Figure 2B). No
significant variation in choice of sex was found across years.
Aerosol Exposure Overturns the Intravenous Route for
Infection
The proportion of articles reporting to induce experimental M.
tuberculosis infection through aerosol exposure rose significantly
(linear-by-linear association p= 0.002) between 1997 and 2009
(Figure 3A). The use of the intravenous route – originally the most
recurrent method – decreased (linear-by-linear association
p,0.001), whereas the use of the intratracheal route remained
relatively stable throughout the analysed period. The intraperito-
neal route was the least chosen and not reported after 2003.
Method for Euthanasia is Seldom Reported
The method for euthanasia was seldom reported (Figure 3B):
80% (259/325) of the articles omitted this information, with no
significant differences between years. Moreover, when information
on euthanasia was given (66/325), it was often incomplete and
therefore difficult to interpret. For example, anaesthetic overdose
was often reported without indicating the route, compound or
dose, and exsanguination was frequently referred to with no
indication whether under anaesthesia or not. Amidst articles
reporting method of euthanasia, CO2 asphyxiation was the most
frequently (44%; 29/66) method referred to.
Rising Trend in Reporting Regulatory Compliance
By 2009, the great majority of articles (80%) reported some type
of regulatory compliance: approval by national authorities or
institutional committees (59%) or compliance with national or
institutional guidelines (21%). This contrasts with the panorama in
1997, when only 6% of the articles mentioned institutional
approval of the experiment. This represents a significant increase
in reporting regulatory compliance of any kind (linear-by-linear
association p,0.001), as well as for reports of ethical approval
(linear-by-linear association p,0.001) (Figure 4A).
Most Studies Terminated before Animals become
Moribund
The majority of the studies analysed were terminated before
infected animals reached very severe morbidity (58%, 188/325),
whereas the remaining allowed mice to reach terminal stages, with
no significant variation of this proportion across years. Amidst all
studies, 42% (137/325) were classified as Level 4, 28% (90/325)
Figure 1. Triage of articles for analysis.
doi:10.1371/journal.pone.0047723.g001
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were classified as Level 3, 30% as Level 2 (96/325) and less than
1% (2/325) as Level 1 (Figure 4B). Among studies explicitly
reporting ethical approval (123/325), 21% (26/123) were classified
as Level 2, 30% (37/123) as Level 3 and 46% (59/123) as Level 4.
Increased Implementation of Humane Endpoints in
Recent Years
Spontaneous death was the chosen endpoint for 66% of lethal
studies (i.e., those conducted on very susceptible mouse strains and
presenting rapidly progressive disease; or in more resistant strains
with recrudescent disease; n = 165). Reported implementation of
humane endpoints in lethal studies tended to be higher (linear by
linear association p= 0.06) in later years when compared with the
first years analysed, with 16% of lethal studies published between
1997 and 2003 (12/76) and 28% of such studies published
between 2005 and 2009 (25/89) reporting the implementation of
humane endpoints (Figure 5A).
The proportion of lethal studies explicitly reporting the
implementation of humane endpoints was significantly higher
(p = 0.014) for articles stating regulatory compliance (25/82) than
for those that did not (12/83). However, 87% (60/70) of all lethal
studies explicitly stating ethical approval were nevertheless
classified as level 4, most of them (46/60) for allowing animals
to die spontaneously, and the remaining for only implementing
humane endpoints when animals showed signs of very severe
morbidity (i.e., were ‘‘moribund’’) (see Figure 4A). For this reason,
the mere application of humane endpoints was not always
sufficient for a study to be classified below the highest severity
category. Of all 37 lethal studies reporting the use of humane
endpoints, only 10 were scored as Level 3. On the other hand, if a
lethal study was planned so that animals were euthanized prior to
the onset of very advanced disease, humane endpoints would not
be required and the study was classified as Level 3. For this reason,
of all studies on lethal models without any explicit reference to the
use of humane endpoints, 14% (18/128) were classified as Level 3.
Figure 5B shows the overall proportion of lethal studies classified at,
or below Level 4, irrespective of reporting humane endpoints.
Other types of measures to reduce animal distress were
seldom reported. The most common was the administration of
antibiotics in water or food instead of drug delivery through
intragastric gavage, whenever this administration route was
appropriate for the study. This administration route was
reported in 14 out of 18 articles using antibiotics to render
viable bacteria undetectable in the lung, whereas the remaining
four used daily gavage. Overall, gavage for drug delivery was
used in 37 studies, with variable duration, mostly in daily drug
administration regimens. Also, 5 articles out of 27 describing
intramuscular immunizations (most in multiple limbs), reported
anaesthesia prior to this procedure. Environmental enrichment
was only reported in four articles.
Discussion
The present analysis of experimental TB research on murine
models shows that the majority of published studies were
terminated before animals had reached terminal stages of disease
progress. Over a 12-year time period, the proportion of
publications reporting ethical approval increased. However, these
changes had no impact on the severity of experiments, and a
considerable proportion of studies involved end-stages of infection
where animals are severely affected or even allowed to die from
the disease. The increasing number of studies reporting regulatory
compliance nevertheless suggests a growing awareness of research-
ers and scientific journals to the importance of adhering to these
standards. However, the incongruence of having studies reported
to have been conducted according to welfare guidelines, or being
ethically approved, when relevant refinement measures are
apparently absent or inadequate, is in contradiction with the view
of ethical appraisal of protocols as a means to ensure good practice
in animal-based research [30]. The soon-to-be-enacted 2010/63/
EU directive on the protection of animals used for scientific
purposes emphasises the ethical evaluation process as a means to
promote full consideration for the 3Rs and minimize the severity
of animal experiments [31]. These results should hence serve as a
note of caution for animal welfare bodies and competent
Figure 2. Biological characteristics of experimental animals. Reported genetic status (A) and gender (B) of mice used in experimental TB
studies published between 1997 and 2009.
doi:10.1371/journal.pone.0047723.g002
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authorities alike, that in order for the ethical review process to
have a meaningful positive impact on animal welfare, it must be
ensured that recommendations are followed-through and that
proper supervision is carried out by competent personnel.
No mouse strain is capable of eradicating M. tuberculosis and,
depending on the duration of the experiment, all are likely to
develop severe disease and eventually die as a result of the disease
progression [14,15,32] before reaching their natural average life-
span [33]. The most important refinement measure for animal
studies of TB is the implementation of earlier endpoints to curtail
the duration and intensity of suffering. The implementation of
humane endpoints was the most common refinement referred to in
the analysed studies, and their application in lethal studies was
more frequent in later years. However, the higher number of
studies applying this refinement in the second half of the analysed
period was not reflected in an overall reduction of studies
categorized in the most severe level, according to the scale
developed specifically for this study. As the disease resulting from
experimental infection is progressively more severe, disease stage
was a key consideration in the severity classification. The most
severe level (Level 4, in which 42% of the studies were classified)
includes studies in which animal survival is measured and animals
go through end-stages and die from the disease, but also those in
which researchers euthanize animals which are found ‘moribund’.
This latter approach represents a scientifically relevant improve-
ment as it allows researchers to collect tissues from animals
immediately post-mortem and it avoids animals dying from
secondary causes such as dehydration. Ethically this refinement
measure curtails at least the very last part of the disease progress
and it requires researchers to establish a protocol for animal health
and welfare assessment which can potentially be adapted for
earlier endpoints. But as outlined in detail elsewhere [34],
euthanasia of moribund animals addresses only a small proportion
of the animal welfare problems posed by this type of research since
it only avoids unrelieved suffering at the moribund stage that
shortly precedes death. Moreover, even in 2009 74% of the studies
involving end-stages of infection did not report the use of humane
endpoints.
As regards reducing the impact of experimental procedures on
animal welfare, the results are more positive. The intratracheal
route of infection, which we identified as the most problematic for
animal welfare, was only used in 9% of all studies, while aerogenic
infection was increasingly applied over the studied period, being in
2009 the most recurrently used method. This is positive from both
the animal welfare and the scientific perspective, since it is not also
a less invasive but also a more realistic route [11,23,35]. This rise
may partly be due to more laboratories having access to the
machine required for aerogenic infection, an apparatus that not
only is expensive but also requires extra safety measures, for
generating M. tuberculosis aerosol.
The rising trend on articles published on murine TB between
1997 and 2009 suggests a growing interest for the use of these
models by the infectious diseases research community. This also
indicates that non-animal models have not yet become as relevant
for basic and applied research as the experimental infection of
animals.
The predominance of studies using only female mice for all the
years analyzed is contrary to the previously reported bias towards
male animals in biomedical research [36,37]. The most probable
explanation is that researchers prefer female mice for long-lasting
studies to avoid the problems with intra-group aggression in male
mice, which often lead to injuries, the need to separate animals or
even terminate the experiment prematurely. One third of the
articles did not report which sex of mice were used, whereas
almost every article reported the strain and genetic status of the
mice used. These data are fairly in agreement with a survey on the
quality of reporting of animals research [38], where 35% of articles
analysed did not disclose mice sex, whereas all of them described
the strains used. Omitting information on sex, as well as on other
parameters, might cause difficulties for the replication of such
studies [39]. Although sex is likely to play a less relevant role in the
immune response of mice to TB when compared to other factors,
it should nonetheless be considered in the interpretation of
research results, since gender differences in susceptibility to TB
have been reported in both humans and other animals (for mice,
see [40,41,42]), suggesting sex to be biologically relevant in the
immune response to mycobacteria [43,44].
Information on other important methodological aspects such as
details on handling and procedures, method of euthanasia as well
as experimental outcome related to animal health status such as
body weight variation and general animal health, were seldom
reported (data not shown). Thus, one cannot exclude that some of
Figure 3. Choice of experimental methods. Route(s) of infection
(A) and method of euthanasia (B) reported for TB studies using mouse
models across 1997–2009.
doi:10.1371/journal.pone.0047723.g003
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the studies did apply refinement measures, without specifically
mentioning them in the publications. In the particular case of
humane endpoints, however, the wording often chosen (‘‘animals
died’’ or ‘‘animals were found dead’’) strongly suggested that the
endpoint was indeed spontaneous death rather than euthanasia.
Information on refinement and on animal health may have been
excluded for space constraints or for not being considered a central
issue for the study, but omitting this information limits the value of
the paper and the possibility to replicate and to share valid
information for the design of more refined experiments [45].
Raising standards in reporting of animal experiments has been of
increasing concern (e.g. [46]), and new standard guidelines [47],
and a ‘‘gold standard publication checklist’’ for improving quality
of animal studies have recently been proposed in order to improve
the reproducibility of experiments, as well as facilitate systematic
reviews [48]. None of these guidelines, however, stress the ethical
Figure 4. Reporting regulatory compliance and overall severity of studies across 1997–2009. In graph A, the dotted line represents the
sum of articles declaring ethical approval (diamonds) and those reporting compliance with legislation or animal care guidelines (squares) for each
year. Graph B illustrates the proportion of articles attributed to severity levels 2, 3 and 4 (the number of Level 1 studies – only 2 out of 325 - was
negligible and is therefore not shown) for each year.
doi:10.1371/journal.pone.0047723.g004
Figure 5. Disease stage at time-of-euthanasia in lethal studies. In Graph A the reported implementation of humane endpoints is shown, with
these being classified as regards their effectiveness in preventing animals reaching near-death morbidity. Graph B illustrates the proportion of lethal
studies (N = 165) classified as, or below, Level 4 severity (on account of being terminated before animals reached terminal stages), irrespective of
humane endpoints being explicitly reported or not. Number of lethal studies distributed by year as follows: 8 in 1997; 26 in 1999; 18 in 2001; 24 in
2003; 25 in 2005; 26 in 2007; 38 in 2009.
doi:10.1371/journal.pone.0047723.g005
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and scientific relevance of humane endpoints, and the importance
of reporting their implementation when publishing animal studies.
The proportion of articles reporting guideline compliance or
ethical approval increased significantly over the 12-year period so
that in 2009, 80% of articles included such a reference. These
results suggest an increasing attention from authors as well as
referees and editors to the ethical issue of animal research and the
importance of ensuring compliance with regulatory mechanisms.
Reference to ethical approval was more frequent for more severe
studies (Levels 3 and 4), and the unexpected observation that the
most frequently attributed severity classification for ethically
approved studies was Level 4 may be an artefact of this tendency.
Although it has been suggested that the main influence of ethics
committee review is an increased application of refinement [49],
this does not necessarily mean that one would not find highly
invasive studies among those having undergone ethical approval.
First, most ethics committees review both animal harm and
potential human benefit [50] and would approve also severe
procedures with animals if scientifically justified. Second, most
animal ethics committees would probably consider the conven-
tional application of humane endpoints a sufficient refinement of
an end-stage experiment, even though we would question the
efficiency of this measure in reducing animal suffering [34].
Conclusion
Overall, this analysis demonstrates indicators of progress on
ethical approval of experiments, application of humane endpoints
and use of less aggressive routes of infection, but there is much to
be done as regards the implementation of refinement, in particular
on defining endpoints with a more relevant impact on animal
wellbeing. Of course, such measures should not be taken to the
expense of research quality and relevance. The best way to avoid a
conflict between ethical constraints and scientific motivations is
probably for scientists to be proactive and initiate a critical
discussion within their own field, rather than awaiting limitations
imposed from outside. In the field of experimental studies of
important infections such as TB, a reassessment of the need for
such a large proportion of studies to involve end-stages of the
disease seems particularly pertinent.
Materials and Methods
Data Retrieval
We analysed articles published on murine models of M.
tuberculosis infection published between 1997 and 2009, the first
year coinciding with the date from which many journals provide
digital access to full-text articles and the last with the most recent
full calendar year for which journal material was available (without
being subject to subscription-only embargos) at the time of data
retrieval. To obtain a manageable sample size representing the full
time-span, articles from every second year (i e 1997, 1999, 2001,
2003, 2005, 2007, 2009) were retrieved. This search was
performed in October 2011 by applying the query TS= ((mouse
OR mice) SAME tuberculosis) AND PY= (1997 OR 1999 OR 2001 OR
2003 OR 2005 OR 2007 OR 2009) on the Advanced Search option in
ISI Web of ScienceH database (4.1 version, no longer accessible).
Search results were refined to exclude articles written in languages
other than English, proceedings papers, editorial material, meeting
abstracts, reviews and correction papers. We screened the
remaining articles in order to only select those reporting actual
infection of mice with M. tuberculosis, hence excluding studies on
humans or other animal models, or in vitro studies and infections
with other mycobacteria (Figure 1).
For each article, reported information on mouse genotypes,
bacterial strains used, infection route, inoculum size, protocol
approval, housing conditions and method for euthanasia were
retrieved, as well as complementary information on animal health
status, weight variation and procedures with considerable animal
welfare impact (such as daily gavage, radiation, potentially
traumatic blood sampling, footpad injection, multiple intramus-
cular injections or intratracheal instillation) and stage of disease
progression at time of euthanasia.
Table 1. Potential causes of pain and distress in studies on experimental infection with M. tuberculosis.
Infection route
Intratracheal instillation Surgical procedure under general anaesthesia: Inoculum delivery through an incision in the trachea, that heals in 2–3
days [52]. Two of the analysed articles reported deaths resulting from this procedure [53,54].
Intraperitoneal injection This injection method offers no possibility to visually confirm correct delivery, and accidental penetration of the
bladder, intestine, muscular or fatty may occur [55,56].
Treatment administration
Intraperitoneal injection Referred above.
Repeated oral gavage Difficult procedure with risk of fluid aspiration by the lungs or perforation of oesophagic or gastric wall. Irritation,
swelling and ulceration of the oesophagus from repeated dosing [56]. Unexpected deaths [57] as well as inappetence
and weight loss [58] reported in experimental infection studies. Reports of increased TB susceptibility due to gavage-
induced stress [59].
Immunization
Footpad immunization Immune reaction to antigen, causing swelling and inflammation in situ, potentially causing pain and lameness [60].
Intramuscular immunization Painful injection that may cause mechanical trauma and potential nerve damage; immune reaction may lead to painful
swelling [56,61].
Health Status
Signs of disease Respiratory distress, hunched posture, lack of grooming [26]; failure to eat or drink, fever, severe cachexia [27].
Increasingly severe clinical signs, progressing to a hypokinetic irresponsive (‘‘moribund’’) state, culminating in death
[23].
doi:10.1371/journal.pone.0047723.t001
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Assessing Severity of Experiments
In Table 1 we briefly describe the most relevant experimental
procedures with an impact on animal welfare, as well as the main
welfare issues raised by the manifestation of active disease.
The severity of individual studies was classified according to a 4-
level scale (Table 2) especially devised for this study, with Level 4
being the most severe. The 2010/63/EU Directive (Annex VIII)
defines severity to be ‘‘determined by the degree of pain, suffering,
distress or lasting harm expected to be experienced by an
individual animal’’ [31]. For the sake of this study, severity
classification was primarily based on the stage of disease animals
were allowed to reach, thus taking into consideration the
cumulative suffering experienced by the animal as a result of
progressive disease. Additionally, the welfare impact of distressful
techniques was also weighed. The Canadian Council on Animal
Care Categories of Invasiveness in Animal Experiments [51] were
used as a basis to build up our scale, which considered available
information on the pathophysiology of the disease in several mouse
strains, as well as the impact of experimental procedures on animal
welfare.
The implementation of humane endpoints was assessed only for
models considered to be ‘‘lethal’’, i.e. all in which disease was
allowed to reach severe stages, either as a result of rapidly
progressive pathology in more susceptible strains or as a result of
long-term evolution of disease in the other strains.
All articles were analysed at least twice by the same person
(NHF), according to the defined criteria for categorization as
described in Table 2.
The following considerations were taken into account for
severity classification:
a) The severity of each study was always the one estimated for
the experimental group sustaining the most severe impact,
such as non-treated groups in drug efficacy studies.
b) The implementation of humane endpoints was assessed only
for those models considered to be ‘‘lethal’’, i.e. all in which
disease was allowed to reach severe stages, either as a result of
rapidly progressive pathology in more susceptible strains or as
a result of long-term evolution of disease in the other strains.
While studies using spontaneous death as an endpoint were
categorized as a Level 4 study, the application of welfare-
relevant humane endpoints [34] allowed for a Level 3
categorization.
c) Unexpected deaths due to experimental procedures or other
non-predicted causes were not considered to justify, per se, a
Level 4 categorization.
d) The estimated noxious impact of research procedures on
welfare for the most invasive procedures – intratracheal
instillation, repeated gavage or footpad immunization – was
considered to justify, per se, a Level 3 categorization.
e) Whenever the available information in each article was seen
as insufficient for reliably assessing disease progression and
outcome, such information would be complemented with
historical data on disease progression and survival for the
given experiments combination of mouse genotype, bacteria
strain, inoculation route and inoculum size (unpublished
data, available upon request). This information was gathered
from 32 articles on the most commonly used inbred mouse
strains, infected by aerosol exposure or the intravenous route.
Whenever doubt persisted on classifying a study in either one
or another of two possible categories, the lower degree of
severity considered was attributed.
f) Alongside humane endpoints in lethal studies, the implemen-
tation of other refinement measures was taken into account
for the categorization of the experiments, namely drug
delivery in drinking water or food (rather than through daily
injections or gavage), anaesthesia, analgesia, or ‘‘gold-
standard’’ control groups (instead of untreated groups) for
drug and vaccine efficacy testing. On the other hand, the use
of invasive and distressful procedures was also taken into
consideration.
g) Both the beneficial (‘‘refinement’’) and detrimental effect of
procedures on welfare were considered. For instance, if
footpad injection was performed, a non-lethal study that
would otherwise be classified as Level 2 would be categorized
as Level 3. On the other hand, if animals were anaesthetized
before undergoing intramuscular injection on multiple limbs,
the latter would not be accounted as distress-inducing
procedure.
Statistical Analysis
Chi-square tests were applied to determine association between
variables. The Mantel-Haenszel linear-by-linear association test
was to assess linear relationship between ordinal variables. The
Table 2. Criteria for severity categorization of experimental studies on murine tuberculosis.
Category Criteria
Level 1 Induction of infection quickly followed by euthanasia, prior to any clinical signs of disease or distress (for example, studies in which animals are
inoculated and euthanized shortly after for in-vitro culture of infected macrophages).
Level 2 Studies of infection in immunocompetent ‘‘TB resistant’’ animals resulting in non-lethal infection with only transient mild symptomology, and
terminated before disease recrudescence; experimental groups given novel drugs or vaccines compared with positive ‘‘gold-standard’’ controls (e.g.
BCG vaccinated animals or groups treated with currently available anti-TB drugs) resulting in sub-clinical or mild signs of the disease in all animals.
Presumably lethal infections terminated before the onset of the most debilitating symptoms. The attribution of Level 2 implicates that no procedures
contemplated as ‘‘Category D’’ or ‘‘Category E’’ by the CCAC are present in the study.
Level 3 Studies resulting in lasting deleterious effects on animal health and welfare, not alleviated by means of refinement. These include: inoculation of
highly susceptible mouse strains unable to effectively control bacterial growth; use of a large inoculate size resulting in very strong immune response
and/or rapidly progressive disease; infection resulting in large pneumonic areas and/or necrotizing tuberculous lesions in the lung; any experiment
contemplating the following invasive procedures: daily gavaging, footpad immunization, intratracheal infection, multiple simultaneous intramuscular
injections (without anaesthesia) or other procedures reported as ‘‘Category D’’ by the CCAC (e.g. radiation-induced sickness).
Level 4 All studies having spontaneous death or ‘‘moribund’’ state as experimental endpoints and/or resulting in severe distress non-alleviated by means of
refinement.
doi:10.1371/journal.pone.0047723.t002
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level of significance used for all tests was 0.05. The statistical
analysis was performed using the software SPSSH.
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